Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196880 | 0.78 | TP53 (0.42) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL607461 | 0.78 | TP53 (0.42) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL1196679 | 0.78 | TP53 (0.42) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL26940411 | 0.74 | MMP1 (0.46) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL29342143 | 0.74 | MMP1 (0.46) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL26940424 | 0.71 | ALDH1A1 (0.42) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL15279752 | 0.70 | RNPEP (0.41) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL13143752 | 0.68 | SLC1A3 (0.43) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL2115319 | 0.68 | TP53 (0.42) | TP53 | |
| SCHEMBL10591095 | 0.64 | SLC1A3 (0.48) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426617-B2 | Asymmetric hydrogenation of alkenes using chiral iridium complexes | DSM IP ASSETS B.V. (NL) | 2013-04-23 | — | — | US | disclosed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | disclosed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | disclosed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | MMP1 3401/4885MMP2 4626/4885MMP3 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.